Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Roche/Genentech get rights to SurModics' technology

Executive Summary

SurModics (drug delivery, medical device coatings, and in vitro diagnostic components) has granted Roche and its Genentech division exclusive rights to apply its biodegradable microparticle drug delivery technology to create a sustained-release version of their wet AMD drug Lucentis (ranibizumab). The agreement also covers additional Genentech ophthalmic compounds.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Macromolecule
      • Site Specific
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing

Related Companies